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Abstract 
Background: Human cytochrome P450 (CYP) enzymes mediate the first step in the breakdown of most drugs and 
are strongly involved in drug–drug interactions, drug clearance and activation of prodrugs. Their biocatalytic behavior 
is a key parameter during drug development which requires preparative synthesis of CYP related drug metabolites. 
However, recombinant expression of CYP enzymes is a challenging bottleneck for drug metabolite biosynthesis. 
Therefore, we developed a novel approach by displaying human cytochrome P450 1A2 (CYP1A2) and cytochrome 
P450 reductase (CPR) on the surface of Escherichia coli.
Results: To present human CYP1A2 and CPR on the surface, we employed autodisplay. Both enzymes were displayed 
on the surface which was demonstrated by protease and antibody accessibility tests. CPR activity was first confirmed 
with the protein substrate cytochrome c. Cells co-expressing CYP1A2 and CPR were capable of catalyzing the conver-
sion of the known CYP1A2 substrates 7-ethoxyresorufin, phenacetin and the artificial substrate luciferin-MultiCYP, 
which would not have been possible without interaction of both enzymes. Biocatalytic activity was strongly influ-
enced by the composition of the growth medium. Addition of 5-aminolevulinic acid was necessary to obtain a fully 
active whole cell biocatalyst and was superior to the addition of heme.
Conclusion: We demonstrated that CYP1A2 and CPR can be co-expressed catalytically active on the cell surface of E. 
coli. It is a promising step towards pharmaceutical applications such as the synthesis of drug metabolites.
Keywords: Surface display, Autotransporter, Autodisplay, Cytochrome P450 1A2, Cytochrome P450 reductase, Whole 
cell biocatalysis
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Background
Microsomal cytochrome P450 monooxygenases (CYPs, 
P450s) are the major enzymes in human drug metabo-
lism as they are involved in the breakdown of almost all 
marketed drugs [1]. As part of the phase-I-metabolism 
these heme-containing proteins catalyze a huge variety 
of oxidation reactions accepting a broad range of endog-
enous and xenobiotic substrates [2]. They hereby convert 
lipophilic into more reactive and hydrophilic metabo-
lites as first step for their elimination from the body. Of 
all 57 human CYPs known, five (CYP3A4, 2C9, 2C19, 
2D6 and 1A2) catalyze the vast majority of drug oxida-
tions. For these class II type CYPs the required electrons 
are supplied from the cytochrome P450 reductase (CPR, 
also referred to as CYPOR) which transfers them from 
nicotinamide adenine dinucleotide phosphate (NADPH) 
through its cofactors flavin adenine dinucleotide (FAD) 
and flavin mononucleotide (FMN) to the heme of the 
monooxygenase [3]. CYP enzymes are an essential deter-
minant for the half-life and safety of a drug and its meta-
bolic products. Consequently, they represent a key factor 
in drug discovery and development. For the complete 
pharmacological characterization of a drug candidate, its 
metabolites must be produced on a preparative scale [4, 
5]. There is a natural interest in exploiting recombinant 
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CYPs for the synthesis of drug metabolites, in particular 
since classical chemical synthesis routes are often very 
challenging and costly [6]. However, as membrane-bound 
proteins, their heterologous expression and purification 
is challenging, laborious and often requires membrane 
preparations to yield active enzymes [7, 8]. For large scale 
applications, the usage of purified CYPs suffers from low 
catalytic activities, purification costs and poor enzyme 
stability.
Many of these challenges can be solved by the appli-
cation of a bacterial whole cell catalyst with surface dis-
played enzymes. The approach is illustrated in Fig.  1. 
Anchorage of the enzyme in the outer membrane of 
Escherichia coli provides a membrane environment and 
circumvents mass transfer limitations due to the mem-
brane barrier. Further major advantages are the cheap 
and easy cultivation, feasibility of large-scale applica-
tions and reusability of the biocatalyst. Additionally, 
common expression hosts like E. coli have no own CYP 
background. As a biotechnological tool for surface dis-
play of recombinant proteins so-called autotransporters 
have been widely employed [9]. They are derived from 
natural outer membrane proteins in gram-negative bac-
teria and their translocation mechanism and structure 
have been intensively studied [10–14]. The technique 
has been successfully applied for the display of a vari-
ety of enzymes such as nitrilase [15], lipase and foldase 
[16], protein kinase CK2 [17] as well as other proteins 
like VHH antibody fragments [18], affibodies [19] and 
peptides [20]. In this study, we employed the two E. coli 
autotransporters AIDA-I [21] and EhaA [22, 23]. For 
surface display, the protein of interest (“passenger”) is 
combined with an N-terminal signal peptide and the 
C-terminal β-domain (also referred as autotransporter 
unit) of the autotransporter which consists of the β1-
(“autochaperone”) domain, α-helix and β-barrel domain 
[12, 22]. After translation the protein is transported 
through the Sec-pathway across the inner membrane 
[14]. The signal peptide is cleaved off and the protein kept 
in an unfolded confirmation by periplasmic chaperones 
such as Skp and SurA. The β-barrel is then inserted into 
the outer membrane with assistance of the Omp85/Bam 
complex while the passenger is translocated to the extra-
cellular space.
Human CYP1A2 has a molecular weight of 58  kDa 
including a 29 amino acid long N-terminal transmem-
brane domain and contains heme b in its catalytic center 
[24]. Known substrates like phenacetin, paracetamol, 
coffein and imipramine are mostly planar polyaromatic 
amides and amines. CYP1A2 catalyzes about 9 % of CYP 
related drug metabolism [1]. The redox partner pro-
tein, the 77 kDa sized human CPR, is composed of a 55 
amino acid N-terminal transmembrane domain, a FMN 
and a FAD/NADPH binding domain which are con-
nected through a flexible hinge region [25, 26]. The CPR 
undergoes conformational changes between an open and 
Fig. 1 Illustration of the biocatalysis by CYP1A2 and CPR on the cell surface. Two electrons are shuttled by the outer membrane (OM) anchored CPR 
from NADPH via the cofactors FAD and FMN in single-electron steps to the heme group of surface displayed CYP1A2. The monooxygenase cata-
lyzes the oxidative breakdown of a substrate by inserting one oxygen atom into the chemical compound while reducing the other one to water. IM 
inner membrane
Page 3 of 15Quehl et al. Microb Cell Fact  (2016) 15:26 
closed form during its redox-cycle, but only the open 
form can transfer electrons to all microsomal CYPs. CPR 
is also able to supply electrons to other redox partners 
such as heme oxygenase and squalene monooxygenase.
Previously, it has been shown that human CYP3A4 
can be displayed in an active form on the surface of E. 
coli using the AIDA-I autotransporter [27]. The obtained 
whole cell biocatalyst was able to convert testosterone 
into 6β-hydroxytestosterone with externally added CPR 
and cytochrome b5. Furthermore, soluble bacterial CYP 
enzymes such as BM3 [28] and CYP106A2 [29] have been 
expressed on the surface of bacteria and used for biocata-
lytic studies. Rat CPR alone has been surface displayed on 
E.  coli using ice-nucleation protein from Pseudomonas 
syringae and was active towards cytochrome c [30]. Dis-
played on Bacillus subtilis spores rat CPR was able to 
transfer electrons to externally added CYP1A2 which was 
shown by 7-ethoxyresorufin-O-deethylation [31]. Belong-
ing to the class I P450 system, mitochondrial bovine 
adrenodoxin has been brought to the surface and was 
active with its externally added redox partners [32] and in 
electrochemical analyses [33] when the iron-sulfur protein 
was reconstituted with supplemented [2Fe–2S] clusters.
In this study, we report on the first successful co-
expression of CYP1A2 and CPR on the surface of E. 
coli. We present experimental evidence that this whole 
cell biocatalyst is functionally active and able to catalyze 
three typical CYP1A2 oxidation reactions.
Results
Vector design
Two compatible expression vectors were constructed 
comprising the human CPR and CYP1A2 coding 
sequences in combination with the necessary autotrans-
porter elements under control of a rhamnose inducible 
promoter. The promoter is tightly regulated and expres-
sion level is well titratable [34]. The obtained fusion 
protein consists of an N-terminal CtxB signal peptide 
for translocation through the Sec pathway, the CPR or 
CYP1A2 passenger without the transmembrane domains 
(amino acids 1–56 and 1–29, respectively) and the C-ter-
minal autotransporter unit for outer membrane anchor-
age (Fig. 2). The CPR was combined with the EhaA and 
CYP1A2 with the AIDA-I autotransporter unit. For clar-
ity, we address these fusion proteins as CPR and CYP1A2, 
respectively. Protein expression was always conducted 
with 1 mmol L−1 rhamnose in the OmpT negative E. coli 
strain BL21(DE3).
Evaluation of surface display by protease accessibility test
To examine surface expression of the two autotrans-
porter fusion proteins, an outer membrane protein isola-
tion (OMPI) was performed and analyzed by SDS-PAGE. 
Additionally, the same portion of the cells was treated 1 h 
at 37 °C with proteinase K prior to the OMPI procedure 
to investigate the protease accessibility of the passengers. 
Protease accessibility is a simple experiment to test the 
surface display of passengers as the protease is regarded 
to be too large to pass the outer membrane and digests 
only proteins exposed on the cell surface. The results 
are shown in Fig.  3. Samples of cells expressing either 
the CYP1A2 or CPR fusion protein contained a distinct 
protein band around the expected apparent molecular 
weight of 103 and 127  kDa, respectively. No compara-
ble band was found in the control sample. In the OMPI 
sample of cells co-expressing the CPR and CYP1A2 
fusion proteins both protein bands were also detectable. 
CYP1A2 is moderately higher expressed likely due to its 
smaller size and the higher plasmid copy number of the 
pBR322 origin of replication (ORI) in comparison to the 
P15A ORI (15–20 to ~10 copies) used for CPR expres-
sion. This would suggest a CYP1A2:CPR ratio above 1, if 
all enzymes were active. Both bands were substantially 
reduced when cells were treated with proteinase K prior 
to OMPI. This demonstrates a clear protease accessi-
bility of the passengers which is a strong indication for 
surface exposure of the passengers. The native outer 
membrane protein OmpA functions as an internal con-
trol for excessive protease treatment. If proteinase K had 
entered the periplasm, the periplasmic domain of OmpA 
would have been cleaved off. This can be detected by dis-
appearance of the OmpA protein band, which, however, 
was unchanged in our experiments. In conclusion, the 
degradation of autotransporter fusion proteins and the 
intactness of OmpA suggest a successful surface display 
of CYP1A2 and CPR.
Evaluation of surface display by flow cytometry 
and immunofluorescence microscopy
Flow cytometry is a common technique to investigate 
surface display of a protein of interest. An antibody does 
not penetrate the outer membrane due to its size and 
only binds to proteins exposed on the cell surface. Only 
for this assay the myc-tag had been genetically intro-
duced in between the passenger and the autotransporter 
unit (Fig.  2). Cells were treated with a myc-tag specific 
primary antibody and a Dylight488 conjugated second-
ary antibody and fluorescence intensities of the cells 
analyzed subsequently via flow cytometry. Fluorescence 
intensities of cells expressing the CYP1A2 (pPQ62) or 
CPR (pPQ61) (Fig. 3b) were significantly higher in com-
parison to the fluorescence intensity of host cells with-
out plasmid indicating the surface exposure of both 
proteins. To confirm these results immunofluorescence 
microscopy analysis of these cells were performed. For 
this purpose, mere host cells, cells expressing CPR with 
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myc-tag (pPQ61, Fig.  2) and cells expressing CYP1A2 
with myc-tag (pPQ62, Fig. 2) were treated with a mouse 
anti-myc antibody and a secondary Dyligh488 conjugated 
anti-IgG antibody and subsequently subjected to confo-
cal laser scanning microscopy. Whereas mere host cells 
did not exhibit immunofluorescence after this treatment, 
CPR and CYP1A2 expressing cells clearly showed such 
fluorescence (Additional file  1: Figure S1). When the 
fluorescence exhibiting cells were treated with protein-
ase K before the antibodies were added, immunofluores-
cence almost completely disappeared (S1). This strongly 
supported the results obtained by flow cytometry  and 
indicated that CPR and CYP1A2 were indeed surface-
expressed. Introduction of the myc-tag did not change 
Fig. 2 Schematic depictions of the expression vectors for the CPR (a) and CYP1A2 (b) autotransporter fusion proteins. The expression cassettes 
consist of the rhamnose inducible promoter (RhaP), the CtxB signal peptide (SP), passenger (CPR: orange, CYP1A2: red), a connecting region (grey) 
and the C-terminal parts of the autotransporter AIDA-I or EhaA comprising the β1-domain (β1), α-helix (α) and β-barrel. The connecting region 
between the CPR and the EhaA is composed of TEV, factor Xa and OmpT protease cleavage sites, a PEYFK epitope and a 15 amino acid long flexible 
glycine/serine (G4S)3 part (pPQ29). For flow cytometry analysis the myc epitope (Myc) was inserted in between the passengers and autotransporter 
unit yielding pPQ61 (CPR) and pPQ62 (CYP1A2). The N-termini of the fusion proteins are expanded as white arrows to show the DNA- and amino 
acid sequences. Plasmids for CYP1A2 autotransporter fusion protein expression (b) contained the pBR322 ori and β-lactamase gene as selection 
marker (bla) and plasmids for CPR autotransporter fusion protein expression (a) the P15A ori and kanamycin resistance (KanR)
Fig. 3 Surface accessibility of CYP1A2 and CPR. a SDS-PAGE of outer membrane protein isolations and investigation of protease accessibility. M: 
Protein marker, apparent molecular weights are indicated on the left. Lane 1–2 sample from E. coli BL21(DE3) host cells, lane 3 sample from cells with 
induced expression of CPR fusion protein, lane 4 sample from cells with induced expression of CYP1A2 fusion protein, lane 5–6 samples from cells 
with induced co-expression of both fusion proteins. Samples in lane 2 and 6 were treated with proteinase K prior to outer membrane protein isola-
tion. b Flow cytometry analyses of immunolabelled cells. Cell samples were treated with a primary monoclonal anti-myc antibody and a secondary 
Dylight488 conjugated anti-IgG antibody, washed and then analyzed via flow cytometry. Grey E. coli BL21(DE3) control cells, red cells expressing 
CYP1A2, orange cells expressing CPR
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the level of protein expression as assessed by OMPI. 
Introduction of the myc-tag did also not influence inter-
action of CPR and CYP1A2. For simplification, however, 
all following experiments were performed with the pas-
sengers without myc-tag.
Cytochrome c activity
First, we investigated the activity of single expressed 
CPR. The reduction of the 11.8  kDa substrate protein 
cytochrome c is a standard assay to investigate the enzy-
matic activity of a CPR [35]. Following NADPH oxidation 
the CPR transfers one electron to cytochrome c which 
can be detected by an absorbance increase at 550 nm. The 
assay was conducted with washed cells (OD578nm 0.25), 
100  µmol L−1 NADPH and 50  µmol L−1 cytochrome c. 
The results are shown in Fig.  4. Cells expressing CPR 
exhibit an activity of about 0.32 µmol L−1 min−1 whereas 
neither the host cells without plasmid nor cells express-
ing CYP1A2 on the surface without CPR showed any 
significant activity in comparison to the NADPH control 
without cells. This demonstrates that surface displayed 
CPR binds its cofactors FAD and FMN and hence is 
capable to shuttle electrons from NADPH to cytochrome 
c. Moreover, cytochrome c is not membrane permeable. 
Thus, these results support that the CPR was displayed 
on the cell surface.
7‑Ethoxyresorufin‑O‑deethylation activity
CYP1A2 catalyzes the conversion of 7-ethoxyresorufin 
to the highly fluorescent product resorufin, if electrons 
are supplied by the redox partner protein CPR. We first 
determined resorufin by HPLC analysis to ensure detec-
tion of the product in the assay at low concentrations. 
Cells were cultivated as described in a sodium/potas-
sium phosphate buffered LB-medium for 19.5 h at 23 °C. 
Assays were conducted with washed cells (OD578nm 40), 
1  µmol L−1 7-ethoxyresorufin and a glucose-6-phos-
phate dehydrogenase NADPH regeneration system in 
0.1 mol L−1 potassium phosphate (pH 7.4) for 40 h. An 
exemplary chromatogram is depicted in Fig.  5a with 
resorufin appearing at 7.4  min. From the areas under 
the curve resorufin concentrations were calculated and 
are shown in Fig. 5b. For host cells without surface dis-
played enzymes and cells with surface displayed CPR 
alone resorufin concentration was below 2  nmol  L−1 at 
all conditions examined. For cells with co-expression of 
CYP1A2 and CPR, significant amounts of resorufin were 
detectable, with 124  nmol  L−1 resorufin in case of an 
expression at 23 °C. This clearly indicates that surface dis-
played CYP1A2 is catalytic active when it is co-expressed 
with surface displayed CPR. An almost tenfold decrease 
in activity was observed at an expression temperature of 
30 °C (14 nmol L−1 resorufin), indicating that enzymatic 
activity depended strongly on the temperature during 
expression. A lower expression temperature was favora-
ble which has been reported for CYP enzymes expressed 
in bacteria in several studies before and appeared to con-
tribute to better folding [7]. The protein expression level 
of CYP1A2 was obviously increased at 30 °C in compari-
son to 23 °C as shown by the OMPI samples (Additional 
file  2: Figure S2 A), demonstrating that the lower activ-
ity as observed is not caused by a lower expression rate, 
but rather due to an unfavorable protein folding. In con-
trast, expression of CPR was unchanged in comparison 
to expression at 23 °C. Both passengers were completely 
accessible by proteinase K, indicating that these pro-
teins were displayed at the cell surface. To our surprise, 
cells expressing CYP1A2 alone were also active but on a 
low level from 9 nmol L−1 (when expressed at 30  °C) to 
19 nmol L−1 (at 23 °C).
Effect of growth medium ingredients on activity
It has been reported for purified CYP enzymes that the 
concentrations of mono- and divalent cationic ions and 
the ionic strength can induce conformational changes 
in the protein structure, affect membrane insertion and 
influence the interaction between partner proteins with 
a significant impact on activity [36–41]. In case of our 
novel biocatalyst, folding takes place outside the cell on 
the outer membrane and could be influenced by the sur-
rounding medium. In consequence, the salt composition 
of the growth medium would have an effect on activity. 
To investigate this effect, potassium and sodium phos-
phate buffered LB-medium as well as several buffered 
LB medium variants with different NaCl concentrations 
were tested and—as a read out—the resorufin production 



























Fig. 4 Cytochrome c activity. Cytochrome c reduction by whole 
cells (OD578nm 0.25) was measured at 550 nm. Reaction was started 
by addition of 100 µmol L−1 NADPH. (1) Assay without cells, (2) E. coli 
BL21(DE3) cells, (3) cells expressing the CYP1A2, (4) cells expressing 
CPR
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of cells grown in these different media was determined. 
Standard LB-medium is composed of 10  g  L−1 NaCl, 
5  g  L−1 yeast extract and 10  g  L−1 peptone. We deter-
mined the reaction product resorufin in the correspond-
ing sample supernatants using a microplate reader and 
set the results into relation to the components added to 
LB (Fig. 6). As shown in Fig. 6a, there was a severe effect 
of the buffer used on resorufin production. Cells culti-
vated in LB medium buffered with 50 mmol L−1 sodium 
phosphate buffer were fourfold less active (44 nmol L−1 
resorufin) than the equivalent cells grown with potassium 
phosphate buffer (182  nmol  L−1 resorufin), and still 2.5 
fold less active than the equivalent with a mixed sodium/
potassium phosphate buffer (112 nmol L−1 resorufin). In 
this case, increasing the Na+ concentration appeared to 
have a negative effect. However, as shown in Fig. 6b, var-
ying the NaCl content of potassium phosphate buffered 
LB medium resulted in the highest product titer with 
5 g L−1 NaCl. Less than 5 g L−1 NaCl led to a significant 
reduction in resorufin production. These results suggest 
Fig. 5 Conversion of known CYP1A2 substrates. a HPLC chromatogram of samples from the 7-ethoxyresorufin-O-deethylation assay. Samples 
were diluted 1:1 with methanol prior to HPLC analysis. (1) Resorufin standard (10 nmol L−1), (2) co-expression sample without substrate in the assay, 
(3) host cells, (4) cells displaying CPR, (5) cells displaying CYP1A2, (6) cells expressing CYP1A2 and CPR. b Resorufin formation in the whole assay 
determined by HPLC following expression at 23 or 30 °C. c HPLC chromatogram of samples of the phenacetin-O-deethylation assay. (1) Paracetamol 
standard (10 µmol L−1) with 8.0 min retention time, (2) 3-acetamidophenol internal standard (10 µmol L−1) with 10.5 min retention time, (3) control 
sample with co-expression cells without substrate, (4) host cells, (5) cells displaying CPR, (6) cells displaying CYP1A2, (7) cells displaying CYP1A2 and 
CPR. d MultiCYP activity measured by luciferin formation. Blank: Control sample without cells
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that the NaCl concentration is a critical parameter for 
defining an optimal growth medium. In our experiments 
potassium buffered LB medium containing 5 g L−1 NaCl 
turned out to be the growth medium yielding the highest 
enzymatic activity of the whole cell biocatalyst towards 
resorufin.
The effects of 1  mmol  L−1 CaCl2 and/or MgCl2 as 
medium additives were also studied. The results are 
shown in Fig.  6c. Addition of MgCl2 to LB medium 
had no effect on product titer and thus CYP1A2 activ-
ity. In contrast, supplementation of the growth medium 
with CaCl2 led to an increase in resorufin production 
by approximately 30  %. None of the tested conditions 
altered the level of protein expression as analyzed by 
OMPI (Additional file  2: Figure S2 B). In summary, our 
results indicate that the activity of surface displayed CYP 
enzyme is strongly influenced by the concentrations of 
Na+, and Ca2+, as well as the buffer used for the growth 
medium. One possible reason could be that these altera-
tions influence protein folding or membrane insertion 
as it has been reported before for purified CYPs [41, 56]. 
Similar observations have not been reported yet for any 
other recombinant surface displayed enzyme.
Secondly, we were interested how heme b needs to 
be provided for a fully functional CYP1A2. The outer 
membrane is considered to be an impermeable bar-
rier for heme. Although LB medium contains about 
5  µmol  L−1 heme [42], E. coli BL21(DE3) is also inca-
pable of actively taking it up due to a lack of heme 
uptake transporters in the outer membrane [43–45]. It 
was previously found that surface displayed CYP3A4 
and CYP106A2 were active without external addition 
of heme [27, 29]. Hence, we investigated if supplemen-
tation of the precursor 5-aminolevulinic acid (5-ALA) 
affects the enzymatic activity of the whole cell biocat-
alyst and if it is a limiting factor. Heme is synthesized 
in the cytoplasm from eight 5-ALA molecules and can 
be translocated to the periplasm (e.g. for periplasmic 
cytochrome c maturation [46]) and to the cell exterior 
through the TolC channel [47, 48]. For this experi-
ment, potassium phosphate buffered LB medium (as 
control) or potassium phosphate buffered LB either 
supplemented with 62.5  µmol  L−1 hemin chloride, or 
with 500  µmol  L−1 5-ALA or with the standard sup-
plementation of 500  µmol  L−1 5-ALA and 4  µmol  L−1 
hemin chloride was used. Hemin chloride is the corre-
sponding salt of heme b. As shown in Fig. 6d, resorufin 
was detectable using co-expression cells grown in LB 
medium without supplementation. Addition of hemin 
led to a 25 % increase in activity in comparison to non-
supplemented LB medium. In contrast, addition of the 
equivalent amount of 5-ALA increased the activity by 
400 % to 169 nmol L−1 resorufin. Thus, CYP1A2 activ-
ity was effectively enhanced through the route of endog-
enous biosynthesis of heme but hardly through addition 
of external heme. Although there is little knowledge 
about the cellular mechanism of cofactor insertion into 
surface displayed enzymes, the results of this approach 
clearly indicated that 5-ALA is a key medium compo-
nent and should be considered in case of future bio-
process optimization.
MultiCYP activity
To test a second common substrate, we applied the so-
called MultiCYP assay (Promega). The measurement of 
activity relies on the O-demethylation of the MultiCYP 
Fig. 6 Effect of growth medium components on 7-ethoxyresorufin-
O-deethylation. a Effect of 50 mmol L−1 phosphate buffer in LB 
medium with 500 µmol L−1 5-ALA and 4 µmol L−1 heme. NaPO4: 
sodium phosphate buffer, Na/KPO4: mixed sodium/potassium phos-
phate buffer (37 mmol L−1 Na+/12 mmol L−1 K+), KPO4: potassium 
phosphate buffer. b Variation of NaCl content in 50 mmol L−1 potas-
sium phosphate buffered LB supplemented with 500 µmol L−1 5-ALA 
and 4 µmol L−1 heme. c Effect of CaCl2 and MgCl2 (each 1 mmol L
−1) 
in potassium phosphate buffered LB medium supplemented with 
500 µmol L−1 5-ALA and 4 µmol L−1 heme. d Effect of heme and 
5-ALA supplementation. Protein expression was conducted in potas-
sium phosphate buffered LB medium with either 4 µmol L−1 heme, 
62.5 µmol L−1 heme, 500 µmol L−1 5-ALA or 500 µmol L−1 5-ALA and 
4 µmol L−1 heme
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substrate to a proluminescent d-luciferin ester, which 
can then be detected by luminescence after the addition 
of an esterase and a luciferase containing detection rea-
gent (LDR). Washed cells expressing surface displayed 
CPR, CYP1A2 or both were suspended in the Multi-
CYP substrate. After 24 h of incubation the formation of 
D-luciferinester was determined (Fig.  5d). For this pur-
pose the resulting luminescence was compared to the 
luminescence values of a d-luciferin calibration curve 
(not shown). Cells with surface displayed CYP1A2 and 
CPR produced a significant higher luminescence signal 
in comparison to cells with only CYP1A2 or CPR, and 
also in comparison to cells with no plasmid, or control 
samples without any cells. These results underline that 
CYP1A2 and CPR were functionally co-expressed and 
it indicates that the MultiCYP assay represents a viable 
method for measuring whole cell activity with surface 
displayed CYPs.
Phenacetin‑O‑deethylation activity
The oxidation of phenacetin to the analgesic drug par-
acetamol is a common first pass reaction and can be 
used to monitor CYP1A2 activity. To examine the reac-
tion, a whole cell assay was performed with 100 µmol L−1 
phenacetin as substrate. After the reaction was stopped, 
samples were spiked with 10  µmol  L−1 3-acetamido-
phenol as internal standard, subsequently extracted 
with diethylether and analyzed by HPLC. The chro-
matogram is shown in Fig.  5c. Only the sample of cells 
co-expressing CYP1A2 and CPR showed a peak at 
the expected retention time for paracetamol (8  min). 
Paracetamol concentration was calculated from the cali-
bration curve to be 1.2 µmol L−1. No peak was observed 
at this retention time in any control. It could be a hint 
that the substrate spectrum of the whole cell biocatalyst 
was not altered in comparison to soluble CYP1A2, as 
at least three known substrates of the free enzyme were 
converted by the whole cell biocatalyst co-displaying 
CYP1A2 and CPR.
Time dependent 7‑ethoxyresorufin‑O‑deethylation by the 
whole cell biocatalyst
Finally, the formation of resorufin was analyzed over a 
time course of 40  h (Fig.  7). For this purpose the assay 
was conducted in 100 mL shake flasks containing 8 mL 
starting volume with 1 µmol L−1 of substrate under vigor-
ous shaking at 200 rpm at 37 °C. Cells had been cultivated 
in potassium phosphate buffered LB-medium supple-
mented with heme, 5-ALA and CaCl2. At the different 
time points, resorufin concentration was determined in 
the supernatant of sample aliquots after depleting the 
cells. The whole cell biocatalyst turned out to be active 
for about 20  h. The final product concentration was 
320  nmol  L−1 and as such moderately higher than the 
product concentration obtained in the 15 mL tube-based 
assay as shown in Fig. 6b. This could have been due to a 
better oxygen supply in the 100 mL shake flasks. When 
cells were harvested after 40  h, washed, adjusted to the 
correct OD and reused in a completely fresh assay, they 
did not show any enzymatic activity at all.
Discussion
In our proof of concept study, we report the first success-
ful co-expression of active human CYP1A2 and CPR on 
the surface of E. coli using autodisplay. We found that the 
cells co-expressing CYP1A2 and CPR on the surface were 
able to catalyze the conversion of three structurally differ-
ent substrates (7-ethoxyresorufin, MultiCYP and phen-
acetin). However, the observed activities were quite low. 
In our case, the biocatalytic activity would be equivalent 
to an average of 175 active CYP1A2 enzymes per cell for 
the phenacetin-O-deethylation. This calculation is based 
on several assumptions. First it was assumed the meas-
ured end-point concentration at 20 h corresponded to the 
initial maximal velocity of the reaction, and second, that 
the turnover number was unchanged during this course. 
For purified human wild type CYP1A2, a kcat value of 
1 min−1 with a KM of 10 µmol L−1 for the phenacetin-O-
deethylation has been reported [49]. The number of cells 
in our assay was calculated to be 3.44 ×  109 cells mL−1 
based on the previously published number of 0.86 × 108 
cells per OD and mL [17]. Hence, the turnover per cell 
would equal 2.9 × 10−13 nmol min−1 for a 20 h reaction 
time. This is only a rough estimation, but it can help to 


















Fig. 7 Time dependent characterization of 7-ethoxyresorufin-O-
deethylation activity. The whole cell assay was performed with 
1 µmol L−1 7-ethoxyresorufin and NADPH regeneration in a 100 mL 
shake flash with 8 mL starting volume. Concentration of the product 
resorufin was determined in the sample supernatants. Data points 
are the mean of at least two independent biological replica and the 
fluctuation for each data point was for all cases <15 %
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evaluate the efficiency of the whole cell biocatalyst. In an 
analogous calculation, the 7-ethoxyresorufin-O-deeth-
ylation activity would equal 22 active CYP1A2 enzymes 
per cell. In comparison to other whole cell biocatalyst 
systems, reported values for a whole cell assay with intra-
cellularly expressed CYP1A2 and CPR were 88  mg  L−1 
paracetamol with 100 g L−1 cell dry weight within 40 h at 
28 °C which is roughly about 70 fold better than our sys-
tem [50]. In contrast, the observed cytochrome c activity 
for single expressed CPR would equal about 3000–4700 
enzymes per cell. For the cytochrome c reduction by the 
CPR, a kcat value of 3000 min−1 had been reported for the 
wild type enzyme and a kcat value of 1900 min−1 for the 
anchorless CPR [51]. This number lies within the usual 
range from 103 to 105 enzymes per cell reported for auto-
display [52, 53]. Nevertheless, cytochrome c activity of 
CPR can obviously not serve as a predictor for the cat-
alytic activity of CPR with CYP1A2, because of the dif-
ferent binding sites for both proteins with CPR [25, 26, 
37]. When comparing Fig. 3 with Fig. 7, there is a clear 
discrepancy between the amount of protein expressed 
and CYP1A2 enzymatic activity. This could have been 
due either to a reduced functionality of surface displayed 
CYP1A2 molecules or to a restricted interaction between 
CPR and CYP1A2 on the cell surface. But indeed both 
would represent major bottlenecks for the application of 
cells with surface displayed CPR and CYP1A2. An indi-
cation for an altered CYP–CPR interaction would be the 
finding, that truncated and hence soluble CPR is almost 
unable to interact with CYPs, but is almost as active 
towards cytochrome c as the complete enzyme [26, 51]. 
Several reasons need to be taken into account for the 
presumably reduced activity of CYP1A2, independent 
of CPR binding. First, the C-terminus is attached to the 
autotransporter domains which could influence fold-
ing. Second, deletion of the N-terminal transmembrane 
domain, which is necessary in the autodisplay approach 
could influence folding. And finally, CYP1A2 could mis-
fold to some extent during transport leading to a reduced 
number of enzymatically active molecules on the cell 
surface.
Modifying or omitting the N-terminal transmembrane 
domain is a common step in increasing the expression 
and solubility of CYPs [8]. It has been proposed that 
the transmembrane domain does not take part in catal-
ysis, but has the important role to bring CYP and CPR 
close to the phospholipid interface [54, 55]. The mem-
brane surrounding modulates enzymatic activity as CYP 
enzymes are partially immersed in the membrane [56, 
57]. Several studies about CYP1A2 investigated the effect 
of a truncated or modified transmembrane domain and 
did not observe a loss of function, but in some cases 
different catalytic rates [49, 55, 58]. In contrast, it has 
been reported for CPR that the soluble truncated form 
is not able to supply electrons to the monooxygenase 
[59]. Here, we omitted the N-terminal transmembrane 
domain of both enzymes to achieve high expression lev-
els. We did not observe a loss of function of the enzymes 
which supports the hypothesis that the transmembrane 
domain is not essential for the catalytic activity. Further-
more, CYP1A2 and CPR form a catalytically active unit, 
although membrane anchorage has been altered from 
the N- to the C-terminus in both enzymes because of 
the C-terminal membrane anchoring β-barrel used in 
autodisplay. Hence, the unusual C-terminal fusion is fea-
sible for both proteins, but our results indicate that this 
alteration could have modified catalytic properties of the 
enzymes.
The catalytic activity of the whole cell biocatalyst 
implies that CPR is able to interact with CYP1A2 and 
to supply electrons through a transient protein–protein 
binding. This supports the theory that autotransporter 
facilitated anchorage allows lateral movement of the pas-
sengers on the outer membrane and quaternary complex 
assembly of protein partners. For other surface displayed 
proteins, it has been reported that multimerization is fea-
sible [15, 17]. Conclusively, we demonstrated that bacte-
rial surface display facilitates also transient interaction 
between protein partners.
We identified several factors for expression which 
influences activity of the whole cell biocatalyst and 
could be promising parameters for bioprocess optimiza-
tion. The whole cell biocatalyst was tenfold more active 
when grown at 23 °C instead of 30 °C. It has been often 
observed for CYP enzymes that the choice of expression 
temperature was highly important [7]. For surface dis-
played proteins, lower temperatures can also be favorable 
[60]. Furthermore, we found that Na+ and Ca2+ concen-
trations in the growth medium affected the product titer 
of washed cells without affecting the protein expression 
level. Addition of 1 mmol L−1 of CaCl2—but not MgCl2—
was beneficial as the product titer of resorufin increased 
by roughly 30  %. Na+ concentration in the growth 
medium strongly affected CYP1A2 activity. As intracellu-
lar Na+ and Ca2+ concentrations are actively maintained 
in living E. coli cells, it appears likely that processes in 
the periplasm or on the outer membrane are affected 
(e.g. protein folding or membrane insertion of the CYP 
enzymes) as they are directly accessible to changes in 
the medium composition. Nevertheless, only few stud-
ies have investigated the influence of medium parameters 
for surface displayed proteins on E. coli [60], and hence 
much more experiments are necessary to get a deeper 
insight in the influence of growth factors on the efficiency 
of surface display. But it needs to be taken into consid-
eration that an important step towards the setting up of 
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a reliable bioprocess with surface displayed enzymes will 
be to determine the optimal medium for cell cultivation.
To investigate if the supply of cofactors is a limiting 
factor for the activity of the whole cell biocatalyst, we 
focused exemplarily on heme as it is derived from only 
one precursor which can be easily added to the medium. 
E. coli BL21(DE3) is able to completely synthesize heme 
from glutamate via 5-ALA in the cytosol and to transport 
it to the periplasm [46]. The precursor 5-ALA is a com-
mon additive for expression of CYP enzymes [7]. Cells 
co-expressing CYP1A2 and CPR showed resorufin activ-
ity already in unmodified LB medium which was also 
found for surface displayed CYP3A4. However, medium 
supplementation with 5-ALA had a strong positive effect 
on CYP activity and our data suggests that the intracel-
lular biosynthesis of the prosthetic group is a highly lim-
iting factor. In our study, the route of endogenous heme 
was by far more effective than external addition of heme. 
500 µmol L−1 5-ALA increased CYP activity by 400 %. In 
contrast, the equivalent amount of exogenous heme had 
a positive effect of merely 25 %. Secondly, it indicates that 
E. coli is metabolically limited during expression in terms 
of producing sufficient heme from glutamate. There-
fore, this could be a promising starting point for strain 
engineering.
It remains an open question at what stage during trans-
location the surface displayed CYP1A2 and CPR incor-
porate their respective cofactors. One hypothesis is that 
they are incorporated after translocation onto the outer 
membrane and taken from the extracellular medium. 
A second is that they are bound by an at least partially 
folded passenger in the periplasm and then translocated. 
It is controversially discussed whether a partially folded 
passenger can be translocated across the outer mem-
brane. Two mechanisms for translocation—the hair-
pin model and the Omp85 model—have been proposed 
whereas only the latter would be compatible with par-
tial protein folding [10]. We observed that heme derived 
from cells is way more effective for increasing CYP activ-
ity than externally added heme. This could indicate that 
heme is incorporated into CYPs in the periplasm and 
not scavenged from the medium. However, it has been 
suggested that the TolC efflux pump provides intracellu-
larly produced heme by exporting it to the extracellular 
medium from where it can be incorporated into CYPs. 
The outer membrane protein TolC forms a channel with 
efflux pumps in the inner membrane [61]. Thereby, por-
phyrins can be exported from the cytosol to the extracel-
lular space which has been observed when natural heme 
homeostasis was disrupted [47, 48]. Nevertheless, this 
hypothesis does not explain why only heme provided by 
the TolC channel but not by medium supplementation 
would be effectively scavenged from the extracellular 
medium. In case of the CPR, there is little knowledge 
about efflux mechanisms for flavins to the cell exterior 
and periplasm. Although present in LB-medium, E. coli 
cannot take up flavins [62] and synthesizes them instead 
in the cytosol from GTP and ribulose-5-phosphate [63]. 
There are no reports on flavin transporters to the peri-
plasm as periplasmic flavoenzymes are uncommon. 
However, the YeeO multidrug efflux transporter has been 
reported to export FAD and FMN to the medium [64]. 
Thus, it is imaginable that cofactor incorporation takes 
place on the cell surface after translocation. Still, the 
mechanism of incorporation needs further investigation.
Nevertheless, for preparative drug metabolite synthesis 
purposes several issues need to be addressed. First, the 
optimal CYP/CPR ratio should be determined and the 
influence of the N-terminal transmembrane domain fur-
ther tested to improve the biocatalytic activity. Moreover, 
it could be investigated if the usage of inversed autotrans-
porter (type Ve) is beneficial in terms of the catalytic 
properties of surface displayed enzymes. In this case 
the passenger is linked by its N-terminus to the anchor-
age protein which corresponds to the orientation of the 
natural transmembrane domain in the endoplasmic 
reticulum. Secondly, we hypothesize that the activity of 
the whole cell biocatalyst can be reasonably increased by 
a thorough bioprocess optimization in terms of growth 
medium, oxygen supply and NADPH regeneration. 
Thirdly, the co-expression of cytochrome b5 could be 
beneficial for the activity of at least some monooxyge-
nases [65]. Fourthly, CYP1A2 is involved in the metab-
olism of only a small fraction of all drugs. Therefore, an 
important step will be to establish co-expression of the 
CPR with all other major drug-metabolizing CYPs.
Conclusion
For the first time, human CYP1A2 has been successfully 
co-displayed with its reductase CPR on the surface of E. 
coli using the autotransporter system. It demonstrates 
that bacterial surface display is a viable tool for obtaining 
active CYP enzymes. This is an important step toward 
metabolite screening and preparative drug metabolite 
synthesis in a whole cell approach regardless of their 
membrane permeability. It also offers the chance to apply 
flow cytometry for human CYPs for applications such 




The codon-optimized open reading frames (ORF) of 
CYP1A2 [Uniprot:P05177-2] and CPR [Uniprot:P16435] 
were obtained by artificial gene synthesis (GeneArt, 
Regensburg, Germany). For cloning the ligase-free 
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In-Fusion technique was used [66]. Escherichia coli strain 
DH5α was used for all subcloning work. To construct 
the plasmid encoding the CYP1A2-autotransporter 
fusion protein the sequence of the autotransporter unit 
of AIDA-I including the sequence for N-terminal chol-
era toxin B signal peptide (CtxB) was amplified via PCR 
from pSC001 [27] and cloned behind the rhamnose-
inducible promoter into the pJOE2775 vector [34, 67]. 
The coding sequence of CYP1A2 without the transmem-
brane domain (amino acid residues 1–29) was then fused 
between the CtxB and the AIDA-I autotransporter unit 
DNA sequence yielding pPQ33. An overview about the 
fusion protein constructs is given in Fig. 2. For the CPR 
autotransporter fusion protein expression vector, the ori-
gin of replication (ORI) and ampicillin selection marker 
of pPQ33 were exchanged by the P15A ORI from pKE19 
and a kanamycin selection marker from the broad-host 
range vector pBBR1-MCS2 [68]. The CPR ORF without 
transmembrane domain (amino acid residues 1–56) was 
inserted between the CtxB and the codon-optimized 
EhaA autotransporter unit (amino acids 839–1327 of 
the native protein) DNA sequence. The latter was taken 
from pMATE-MT004 [23] and modified to contain a 
TEV, fXa and OmpT cleavage site, the PEYFK epitope 
and an additional flexible (G4S)3 hinge region. The plas-
mid was termed pPQ29. By inserting the sequence for 
the anti-myc epitope tag between the passenger and the 
autotransporter unit into pPQ29 and pPQ33 the plas-
mids pPQ61 and pPQ62 were obtained. The expression 
cassettes of all plasmids were checked by sequencing. E. 
coli BL21(DE3) was used for expression experiments.
Growth medium and culture conditions
Cultivation were performed in lysogeny broth (LB) 
medium containing 10  g  L−1 peptone, 5  g  L−1 yeast 
extract and 10 g L−1 NaCl. Solid media were prepared by 
addition of 1.5 % (w/v) agar. Kanamycin and carbenicillin 
were supplemented to ensure plasmid stability to a final 
concentration of 62.5 and 125 µg mL−1, respectively. Pre-
cultures were performed in unmodified LB medium at 
37 °C overnight. For expression studies LB medium was 
modified. Depending on the experiment LB was buffered 
with either a sodium phosphate buffer, a 37:12 mixed 
sodium/potassium phosphate buffer or a potassium 
phosphate buffer, each set to pH 7 with a final concentra-
tion of 50 mmol L−1 phosphate. Protein expression was 
induced with 1 mmol L−1 l-rhamnose. Using an autoin-
duction approach, 0.5 g L−1 glucose as catabolite repres-
sor was added delaying expression until approximately 
OD578nm 0.5 was reached. Filter sterilized solutions of 
5-ALA and hemin chloride were added to a final concen-
tration of 500 and 4 µmol L−1, respectively. Unless oth-
erwise stated, main cultures were inoculated with 1 mL 
preculture broth in 100 mL medium in a 500 mL shake 
flask and vigorously shaken at 200  rpm. Depending on 
the experiment, induced cells were either cultivated at 
23 °C for 19.5 h or at 30 °C for 10 h.
Outer membrane protein isolation and protease 
accessibility
Outer membrane protein isolation was conducted as 
described in literature [69]. To investigate surface expo-
sure of the passenger the protease accessibility test was 
used. Cells were grown in 100 mL potassium phosphate 
buffered LB medium at 23  °C for 19.5 h and harvested. 
Cells from 33  mL culture broth were re-suspended 
in phosphate buffered saline (PBS). After addition of 
50 mAnson U proteinase K the suspension was kept 
at 37  °C for 1 h. The digest was stopped by addition of 
1 mmol L−1 PMSF and washing three times with 5 mL of 
pre-cooled 0.2 mol L−1 Tris buffer (pH 8). The cells were 
then re-suspended in 1.5 mL 0.2 mol L−1 Tris buffer and 
further processed in the outer membrane protein prepa-
ration. Samples from the OMPI were boiled 20  min at 
95  °C in SDS-PAGE sample buffer with 30  mmol  L−1 
dithiothreitol and separated with a 10 % acrylamide gel. 
Proteins were stained with Coomassie Brilliant Blue 
G-250.
Flow cytometry analysis
To probe surface exposure of the passenger, cells were 
analyzed by flow cytometry after treatment with fluo-
rescence labelled antibodies. Cells were grown in 20 mL 
potassium phosphate buffered LB medium in a 100  mL 
shake flask at 23  °C for 19.5  h. After harvest cells were 
washed tree times with filter-sterilized PBS. 1 mL of cells 
(OD578nm 0.2) were treated with 10 µg mL−1 monoclonal 
mouse Anti-myc antibody (ThermoFisher Scientific) for 
30 min. Cells were washed three times and then treated 
with 20 µg mL−1 secondary DyLight 488 conjugated goat 
anti-mouse IgG (H + L) Antibody in the dark for 30 min. 
After a final round of washing and re-suspension the flu-
orescence of 50,000 cells was analyzed using a FACSAria 
flow cytometer (BD Biosciences, USA) at an excitation 
wavelength of 488 nm.
Immunofluorescence microscopy
Cells were prepared as described for the flow cytometry 
analysis. Pretreatment with proteinase K was conducted 
as described for OMPI. After antibody incubation and 
subsequent washing steps, cells were re-suspended in 
30 µL filter-sterilized PBS, 10 µL applied on a slide and 
the cover slip sealed with nail polish. Fluorescence images 
were obtained with a confocal laser scanning microscope 
TCS SP2 (Leica, Wetzlar, Germany) at 488 nm excitation 
using an Argon laser.
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Cytochrome c assay
The whole cell assay was performed as described for puri-
fied enzymes [35]. Cultivation was performed with 20 mL 
medium without hemin and 5-ALA at 23  °C in 100  mL 
shake flask for 19.5  h. Cells were harvested and washed 
three times in potassium phosphate buffer (pH 7.6.). The 
assay was conducted in a 96-well microplate with cells at 
a final OD578nm of 0.25, 50  µmol L−1 cytochrome c and 
100  µmol L−1 NADPH at 30  °C. Absorbance of reduced 
cytochrome c was measured at 550  nm using an Infinite 
200 Pro reader (Tecan Group, Männedorf, Swiss). Concen-
trations were calculated with the molar extinction coeffi-
cient of 21 mmol−1 cm−1 and a path length of 0.29 cm.
7‑Ethoxyresorufin‑O‑deethylation assay
CYP1A2 catalyzes the oxidative O-deethylation of the 
test substrate 7-ethoxyresorufin to the highly fluorescent 
resorufin. Cells were harvested and washed three times 
in 0.1 mol L−1 potassium phosphate buffer (pH 7.4). The 
enzyme reaction was carried out in a 15 mL reaction tube 
with 0.8 mL total volume containing whole cells (OD578nm 
40), 1 µmol L−1 7-ethoxyresorufin and a NADPH regen-
eration system in 0.1  mol  L−1 potassium phosphate 
buffer (pH 7.4). 7-ethoxyresorufin was prepared as 
1 mmol L−1 stock solution in DMSO and stored at 4  °C 
protected from light. The regeneration system consisted 
of 250  µmol  L−1 NADP+, 1  mmol  L−1 glucose-6-phos-
phate and 1  µg  mL−1 of purified glucose-6-phosphate 
dehydrogenase from E. coli which were pre-incubated at 
37 °C before addition. The reaction tube was shaken hori-
zontally at 37  °C for 40 h and protected from light. The 
assay was terminated by removal of the cells through cen-
trifugation. Depending on the experiment resorufin for-
mation was either determined by HPLC analysis or in a 
microtiter plate assay.
Resorufin measurement
For HPLC analysis of resorufin formation a LiChrospher 
60 RP-select B column 250-4 (5 µm) from Merck (Darm-
stadt, Germany) was used in a LaChrom Elite System 
equipped with a fluorescence detector L-2485. The 
mobile phase consisted of 50  % methanol and 50  % 
0.05  mol  L−1 potassium phosphate buffer (pH 7). The 
system was run at a flow rate of 0.6 mL min−1. Injection 
volume was 40 µL. The retention time for resorufin was 
7.4 min and for 7-ethoxyresorufin 29 min. Fluorescence 
was measured at 590 nm using excitation at 550 nm. To 
save measurement time a sample run was 10 min. Prior 
to analysis, sample supernatant were diluted with metha-
nol 1:1, centrifuged 10 min at 10,000g to remove precipi-
tates and then filtered through a 0.2  µm PTFE syringe 
filter. Resorufin was quantified with a standard curve 
ranging from 1 to 200 nmol L−1.
For microtiter plate analysis 100  µL of the sample 
supernatant were analyzed fluorometrically in a 96 
well plate using Infinite 200 Pro reader (Tecan Group, 
Männedorf, Swiss). Fluorescence was determined at 
590 nm with excitation at 550 nm. Resorufin was quanti-
fied using a standard curve made in the supernatant from 
co-expression assay samples without substrate treated as 
described before.
Phenacetin‑O‑deethylation measurement
Cells were cultivated in potassium phosphate buffered 
LB medium additionally supplemented with 1 mmol L−1 
CaCl2. Assay conditions were the same as for the 7-eth-
oxyresorufin-O-deethylation except that 100 µmol L−1 of 
phenacetin were used. After 40 h incubation 10 µmol L−1 
of the internal standard 3-acetamidophenol was added 
and the reaction terminated by addition of 4 mL diethy-
lether to 800 µL L−1 of assay volume. The samples were 
vortexed for 10  min, centrifuged and the water phase 
frozen. The organic layer was collected, 65 µL 1 mol L−1 
HCL added to the water phase and the extraction proce-
dure repeated. The collected diethylether was removed 
under N2 stream and samples were dissolved in 150  µL 
30 % methanol/70 % 0.1 mol L−1 acetate buffer pH 4.
Paracetemol content was determined via the HPLC 
LaChrom Elite System. 40  µL sample aliquot were sepa-
rated using a LiChrospher 60 RP-select B column 125-4 
(5  µm) from Merck (Darmstadt, Germany) and eluted 
with methanol/H2O (0.1  mol L−1 acetic acid pH 4) 
through a linear gradient from 5 to 30  % methanol for 
11 min at a flow rate of 0.6 min mL−1. The solvent mix-
ture was then kept constant for 3 min. The column was re-
equilibrated for 6 min with 5 % methanol. Absorption was 
recorded at 250 nm. Retention times for paracetamol and 
3-acetoamidophenol were 8 and 10.5  min, respectively. 
Each substance was quantified with a standard curve 
ranging from 0.5 to 100 µmol L−1. Paracetamol assay con-
centrations were calculated with regard to the extraction 
recovery factor determined through the internal standard.
Luciferin‑MultiCYP assay
The luciferin-MultiCYP assay represents a method for 
the measurement of CYP activity. MultiCYP is a non-
selective proluminescent substrate which is convertible to 
d-luciferin ester by at least 21 CYPs, including CYP1A2 
[70]. Protected from light, a 50 mmol L−1 MultiCYP stock 
solution in acetonitrile and a 2 mmol L−1 stock solution 
of d-luciferin in water were made and stored at −20  °C. 
Cells were grown as described, harvested and washed 
two times in 0.2 mol L−1 potassium phosphate buffer (pH 
7.4). Cells (OD578nm 20) were incubated under continu-
ous shaking in 2 mL reaction tubes at 37 °C in 0.1 mol L−1 
potassium phosphate buffer (pH 7.4) with 50  µmol  L−1 
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MultiCYP and 200  µmol  L−1 NADPH with a total vol-
ume of 120 µL. After 24 h, cells were sedimented (2 min, 
14000 rpm), the supernatant was collected and incubated 
at 90 °C for 10 min (to prevent ATP hydrolysis by remain-
ing cell components). Denatured cell components were 
removed by centrifugation (2 min, 14,000 rpm) and 50 µL 
supernatant was transferred to white microtiter plates, 
where 50 µL luciferin detection reagent was added. After 
20  min of incubation at 30  °C, luminescence was meas-
ured for 10  min and compared to a d-luciferin calibra-
tion curve (0–2 µmol L−1). Uptake of luciferin by cells was 
excluded by incubation of d-luciferin with or without cells 
under assay conditions and subsequent measurement of 
the resulting luminescence. Heat stability of d-luciferin 
was determined by incubation of d-luciferin under assay 
conditions at 90 °C for 10 min.
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